Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Upstream Bio, Inc.NASDAQ: UPB
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock broadly unchanged from a year ago
Common stock stood at $54K at the end of Q1 FY2026, up 1.9% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +162.1% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +1.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 54K USD
- Year-over-year change
- +1.9%
- 3-year CAGR
- +162.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54K | +1.9% |
| FY2024 | 2024-12-31 | 53K | +1666.7% |
| FY2023 | 2023-12-31 | 3K | +0.0% |
| FY2022 | 2022-12-31 | 3K | — |
Common Stock vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1.9% is the 9th highest of 10, against a peer median of +20.0%.
- Common stock amounts to 0.0% of total assets for UPB, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.63B USD | +37.9% | +26.3% | 278.8% | |
| Sep 2026 | €8.5M EUR | +9.0% | +24.5% | 2.9% | |
| Mar 2026 | $1.68M USD | +2.2% | +23.9% | 0.2% | |
| Jun 2026 | $211K USD | +25.6% | +11.6% | 0.0% | |
UPBUpstream Bio, Inc. | Mar 2026 | $54K USD | +1.9% | +162.1% | 0.0% |
| Sep 2026 | $16K USD | +23.1% | +35.7% | 0.0% | |
| Sep 2026 | $13K USD | +18.2% | +16.3% | 0.0% | |
| Mar 2026 | $12K USD | +20.0% | +10.1% | 0.0% | |
| Mar 2026 | $9K USD | +0.0% | +8.7% | 0.0% | |
| Mar 2026 | $6K USD | +50.0% | — | 0.0% | |
| Peer median (excluding UPB) | — | +20.0% | +20.1% | 0.0% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.